1800011I IDT biologika vaccine manufacturing and characterization services to VM19V8RDB--3 quantity base award IID can 8470036 $367,000.00
Ended Awarded Last action
- Contract number
- 75N93019F00311
- Awardee
-
IDT Biologika GMBH UEI E14GD5J873N9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,723,700
Award facts
- Opportunity
-
- RFPNIAIDDMIDNIHAI2017089 Solicitation number
- Manufacturing and Characterization Services for Vaccines and Other Biologics for Infectious Diseases Award Notice · Posted Jan 27, 2017
- Contract value 100% obligated
- $2,723,700.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Germany
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $67,500 | |
| Original award | $2,656,200 |
About this award
This is a federal delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to IDT Biologika GMBH, a foreign-owned, for-profit biotechnology company based in Germany. The contract, valued at a ceiling of $2,723,700.00, is for vaccine manufacturing and characterization services to support infectious disease research and pandemic preparedness efforts. Specific work includes the development, manufacturing, and characterization of various biological materials such as influenza virus human challenge material, Staphylococcus aureus protein A, toxoid fusion proteins, and SARS-CoV-2 vaccine candidates. The contract has a period of performance through April 18, 2025 and does not have a set-aside designation.
Quick answers
Who was awarded contract 75N93019F00311?
75N93019F00311 was awarded to IDT Biologika GMBH by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 19, 2019.
How much is contract 75N93019F00311 worth?
The government has obligated $2,723,700 on 75N93019F00311.
Is contract 75N93019F00311 an order under another contract?
Yes. 75N93019F00311 is a delivery order under 75N93018D00011, an indefinite delivery contract.
Was contract 75N93019F00311 competed?
The extent of competition for 75N93019F00311 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award